A Phase 3 Randomized Open Label Study to Compare NKTR-214 Combined With Nivolumab to the Investigator's Choice of Sunitinib or Cabozantinib in Patients With Previously Untreated Advanced Renal Cell Carcinoma
A Phase 3 Randomized Open Label Study to Compare NKTR-214 Combined With Nivolumab to the Investigator's Choice of Sunitinib or Cabozantinib in Patients With Previously Untreated Advanced Renal Cell Carcinoma
The main purpose of this study is to compare the objective response rate (ORR) and overall survival (OS) of bempegaldesleukin (NKTR-214: BEMPEG) combined with nivolumab to that of tyrosine kinase inhibitor (TKI) monotherapy (sunitinib or cabozantinib) in IMDC intermediate- or poor-risk patients and IMDC all-risk patients with previously untreated advanced renal cell carcinoma (RCC).
Key Inclusion Criteria:
Key Exclusion Criteria:
Additional protocol defined inclusion/exclusion criteria and exceptions apply
Allentown, Pennsylvania 18103, United States
San Miguel de Tucumán, 4000, Argentina
Saint Leonards, New South Wales 2065, Australia
Salvador, Estado de Bahia 41950-610, Brazil
Belo Horizonte, Minas Gerais 30190-130, Brazil
Porto Alegre, Rio Grande do Sul 90050-170, Brazil
Porto Alegre, Rio Grande do Sul 90610-000, Brazil
São José do Rio Preto, 15090-000, Brazil
Volzhskiy, 404120, Russia